Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC)
EUR 49.04
(-0.93%)
EUR 49.04
(-0.93%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 65.42 Million EUR | -9.3% |
| 2022 | 72.13 Million EUR | -1.38% |
| 2021 | 73.14 Million EUR | -0.51% |
| 2020 | 73.51 Million EUR | -13.18% |
| 2019 | 84.67 Million EUR | 147.42% |
| 2018 | 34.22 Million EUR | -20.85% |
| 2017 | 43.23 Million EUR | 27.94% |
| 2016 | 33.79 Million EUR | -21.0% |
| 2015 | 42.77 Million EUR | 17.83% |
| 2014 | 36.3 Million EUR | 17.2% |
| 2013 | 30.97 Million EUR | -19.31% |
| 2012 | 38.39 Million EUR | -6.92% |
| 2011 | 41.24 Million EUR | -4.28% |
| 2010 | 43.08 Million EUR | 42.41% |
| 2009 | 30.25 Million EUR | 0.0% |
| 2008 | - EUR | -100.0% |
| 2007 | 22.17 Million EUR | 82.29% |
| 2006 | 12.16 Million EUR | -99.99% |
| 2005 | 221.47 Billion EUR | 172818.43% |
| 2004 | 128.07 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 81.77 Million EUR | 24.99% |
| 2024 Q2 | 121.15 Million EUR | 48.16% |
| 2023 Q1 | 69.3 Million EUR | -3.93% |
| 2023 Q4 | 65.42 Million EUR | 2.78% |
| 2023 Q3 | 63.65 Million EUR | -4.28% |
| 2023 Q2 | 66.5 Million EUR | -4.05% |
| 2023 FY | 65.42 Million EUR | -9.3% |
| 2022 FY | 72.13 Million EUR | -1.38% |
| 2022 Q2 | 73.12 Million EUR | 1.16% |
| 2022 Q4 | 72.13 Million EUR | -2.01% |
| 2022 Q1 | 72.29 Million EUR | -1.17% |
| 2022 Q3 | 73.62 Million EUR | 0.67% |
| 2021 Q3 | 71.89 Million EUR | -1.29% |
| 2021 FY | 73.14 Million EUR | -0.51% |
| 2021 Q4 | 73.14 Million EUR | 1.74% |
| 2021 Q2 | 72.83 Million EUR | 0.16% |
| 2021 Q1 | 72.71 Million EUR | -1.09% |
| 2020 Q3 | 74.9 Million EUR | -0.6% |
| 2020 Q4 | 73.51 Million EUR | -1.85% |
| 2020 Q1 | 76.65 Million EUR | -9.47% |
| 2020 Q2 | 75.35 Million EUR | -1.7% |
| 2020 FY | 73.51 Million EUR | -13.18% |
| 2019 FY | 84.67 Million EUR | 147.42% |
| 2019 Q3 | 44.34 Million EUR | -9.63% |
| 2019 Q1 | 50.75 Million EUR | 48.3% |
| 2019 Q2 | 49.07 Million EUR | -3.31% |
| 2019 Q4 | 84.67 Million EUR | 90.94% |
| 2018 Q1 | 40.42 Million EUR | -6.52% |
| 2018 Q2 | 19.38 Million EUR | -52.03% |
| 2018 FY | 34.22 Million EUR | -20.85% |
| 2018 Q4 | 34.22 Million EUR | -13.4% |
| 2018 Q3 | 39.51 Million EUR | 103.82% |
| 2017 FY | 43.23 Million EUR | 27.94% |
| 2017 Q4 | 43.23 Million EUR | -8.21% |
| 2017 Q3 | 47.1 Million EUR | -4.13% |
| 2017 Q2 | 49.13 Million EUR | -4.22% |
| 2017 Q1 | 51.3 Million EUR | 51.8% |
| 2016 Q3 | 37.62 Million EUR | -5.27% |
| 2016 Q2 | 39.72 Million EUR | -4.15% |
| 2016 Q4 | 33.79 Million EUR | -10.19% |
| 2016 Q1 | 41.44 Million EUR | -3.12% |
| 2016 FY | 33.79 Million EUR | -21.0% |
| 2015 Q1 | 35.93 Million EUR | -1.01% |
| 2015 FY | 42.77 Million EUR | 17.83% |
| 2015 Q4 | 42.77 Million EUR | -3.1% |
| 2015 Q3 | 44.14 Million EUR | 26.0% |
| 2015 Q2 | 35.03 Million EUR | -2.51% |
| 2014 Q1 | 30.22 Million EUR | -2.42% |
| 2014 Q4 | 36.3 Million EUR | -2.65% |
| 2014 Q2 | 25.21 Million EUR | -16.59% |
| 2014 Q3 | 37.29 Million EUR | 47.91% |
| 2014 FY | 36.3 Million EUR | 17.2% |
| 2013 Q4 | 30.97 Million EUR | -1.74% |
| 2013 Q3 | 31.52 Million EUR | -1.64% |
| 2013 FY | 30.97 Million EUR | -19.31% |
| 2013 Q2 | 32.05 Million EUR | -15.84% |
| 2013 Q1 | 38.08 Million EUR | -0.79% |
| 2012 Q1 | 43.93 Million EUR | 6.51% |
| 2012 Q2 | 3.76 Million EUR | -91.44% |
| 2012 Q3 | 38.51 Million EUR | 923.79% |
| 2012 FY | 38.39 Million EUR | -6.92% |
| 2012 Q4 | 38.39 Million EUR | -0.32% |
| 2011 FY | 41.24 Million EUR | -4.28% |
| 2011 Q1 | 45.42 Million EUR | 5.43% |
| 2011 Q2 | 43.71 Million EUR | -3.76% |
| 2011 Q3 | 51.84 Million EUR | 18.6% |
| 2011 Q4 | 41.24 Million EUR | -20.45% |
| 2010 Q4 | 43.08 Million EUR | 0.0% |
| 2010 FY | 43.08 Million EUR | 42.41% |
| 2009 FY | 30.25 Million EUR | 0.0% |
| 2008 FY | - EUR | -100.0% |
| 2007 FY | 22.17 Million EUR | 82.29% |
| 2006 FY | 12.16 Million EUR | -99.99% |
| 2005 FY | 221.47 Billion EUR | 172818.43% |
| 2004 FY | 128.07 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Atrys Health, S.A. | 254 Million EUR | 74.241% |
| Biotechnologies Assets SA | 7.12 Million EUR | -818.173% |
| Oryzon Genomics S.A. | 13.68 Million EUR | -378.014% |
| Pharma Mar, S.A. | 43.36 Million EUR | -50.865% |